Patents by Inventor Mark Sommerfeld

Mark Sommerfeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMPOSITION FOR TREATING A METABOLIC SYNDROME
    Publication number: 20130203651
    Abstract: The invention is directed to a pharmaceutical composition containing at least one FGF-21 (fibroblast growth factor 21) compound, at least one GLP-1R (glucagon-like peptide-1 receptor) agonist and optionally at least one anti-diabetic drug and/or at least one DPP-4 (dipeptidyl peptidase-4) inhibitor for the treatment of at least one metabolic syndrome and/or atherosclerosis, in particular diabetes, dyslipidemia, obesity and/or adipositas.
    Type: Application
    Filed: January 21, 2011
    Publication date: August 8, 2013
    Applicant: SANOFI
    Inventors: Mark Sommerfeld, Hans-Ludwig Schaefer, Oliver Boscheinen, Paul Habermann, Ercole Rao, Matthias Dreyer
  • NOVEL INSULIN DERIVATIVES HAVING AN EXTREMELY DELAYED TIME-ACTION PROFILE
    Publication number: 20110173722
    Abstract: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the addition and/or substitution of negatively and positively charged amino acid residues and by an amidation of the C-terminal carboxy group of the B chain and histidine in position 8 of the insulin A chain. The invention also relates to the production and use thereof.
    Type: Application
    Filed: June 22, 2010
    Publication date: July 14, 2011
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Paul HABERMANN, Gerhard SEIPKE, Roland KURRLE, Gunter MULLER, Mark SOMMERFELD, Norbert TENNAGELS, Georg TSCHANK, Ulrich WERNER
  • NOVEL INSULIN DERIVATIVES HAVING AN EXTREMELY DELAYED TIME-ACTION PROFILE
    Publication number: 20110077197
    Abstract: The invention relates to novel insulin analogs having a basal time-action profile, which are characterized by the following features: a) the B chain end consists of an amidated basic amino acid residue such as lysine or arginine amide; b) the N-terminal amino acid residue of the insulin A chain is a lysine or arginine radical; c) the amino acid position A8 is occupied by a histidine radical; d) the amino acid position A21 is occupied by a glycine radical; and e) one or more substitutions and/or additions of negatively charged amino acid residues are carried out in the positions A5, A15, A18, B-1, B0, B1, B2, B3 and B4.
    Type: Application
    Filed: June 22, 2010
    Publication date: March 31, 2011
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Paul HABERMANN, Gerhard SEIPKE, Roland KURRLE, Gunter MULLER, Mark SOMMERFELD, Norbert TENNAGELS, Georg TSCHANK, Ulrich WERNER
  • Method for identifying IRS inhibitors or agonists
    Patent number: 7803571
    Abstract: The present invention relates to a method for the identification of an IRS protein kinase inhibitor, comprising the steps of a) bringing into contact PKC-? with at least one IRS peptide comprising at least one PKC-?-Ser-phosphorylation site in the presence of at least one possible inhibitor, and b) measuring the phosphorylation of the PKC-?-Ser-phosphorylation site.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: September 28, 2010
    Assignee: Sanfoi-Aventis Deutschland GmbH
    Inventors: Norbert Tennagels, Jurgen Eckel, Sabine Metzger, Mark Sommerfeld
  • Method for the identification of IRS protein kinase inhibitors or agonist
    Publication number: 20050106653
    Abstract: The present invention relates to a method for the identification of an IRS protein kinase inhibitor, comprising the steps of a) bringing into contact PKC-? with at least one IRS peptide comprising at least one PKC-?-Ser-phosphorylation site in the presence of at least one possible inhibitor, and b) measuring the phosphorylation of the PKC-?-Ser-phosphorylation site.
    Type: Application
    Filed: August 13, 2004
    Publication date: May 19, 2005
    Applicant: Aventis Pharma Deutschland GmbH
    Inventors: Norbert Tennagels, Jurgen Eckel, Sabine Metzger, Mark Sommerfeld